4 NEWS
LSIPR Newsletter 04:14 Sun Pharma to acquire rival Ranbaxy for $3.2bn MUMBAI, INDIA
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.
Te transaction will strengthen Sun Pharma’s product portfolios in dermatology, urology and anti-infectives.
According to a presentation given by the companies on April 7, the transaction will create the fifth largest specialty generic pharmaceutical company in the world, and the largest in India, with 184 Abbreviated New Drug Applications (ANDAs) in its pipeline.
Te combined company’s revenues are estimated at $4.2 billion on a pro forma basis, with yearly earnings of $1.2 billion, in 2013. It will operate in 65 countries and have 47 manufacturing plants in five continents.
Japanese pharmaceutical company Daiichi Sankyo, which holds about 63.4 percent of
UK High Court strikes down Herceptin patents LONDON, UK
Te UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) aſter a challenge by generic drug maker Hospira.
Hospira sought to make a generic version of the blockbuster drug aſter a supplementary protection certificate covering the product expires on July 28, 2014.
It argued that the ‘115 patent, which covers a dosing regime, is obvious and that the ‘455 patent, covering a composition of trastuzumab, lacks novelty over a previous Patent Cooperation Treaty application by Herceptin co-developer Genentech. Hospira did not challenge the product’s underlying patent EP 0,590,058, also held by Genentech.
In the April 10 ruling, Justice Colin Birss found both of the patents at suit to be invalid.
A spokesperson for Roche told LSIPR that it was analysing the court ruling and considering its next steps. She added: “Tere are currently no approved trastuzumab biosimilars in
Europe. Subsequently, we anticipate the impact of this decision will be minimal.”
Hospira said in a statement: “We are very pleased with this decision, which helps pave the way for our trastuzumab product.”
Sun Pharma to merge with Ranbaxy
Patents invalidated
Between 1999 and 2003, worldwide sales for Herceptin totalled 49 billion Swiss francs ($56 billion). European sales from 2010 to 2013 totalled eight billion Swiss francs ($9 billion).” n
www.lifesciencesipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24